
News|Articles|May 12, 2025
For Patients Who Cannot Wait, This Off-the-Shelf CAR NK Treatment for AML Leaves Healthy Cells Alone
First part of a 2-part interview with Stephen Strickland, MD, MSCI, director of leukemia research for Sarah Cannon Research Institute. Strickland recently presented data from a phase 1 trial of SENTI-202, an investigational chimeric antigen receptor (CAR) natural killer (NK) cell therapy.
Advertisement
Advertisement
In some blood cancers, chimeric antigen receptor (CAR) T-cell therapy has been lifesaving. These treatments are engineered with patients’ own T cells to express a synthetic receptor, or CAR, that binds to antigens to set loose a powerful immune response. These treatments can destroy cancer or produce a prolonged response in pediatric leukemia, B-cell lymphoma, and multiple myeloma; for patients lacking options, CAR T can seem like a miracle.
Related to this article

Merck has begun the phase 3 ENHANCE-3 trial testing whether ensifentrine added to standard of care prevents COPD exacerbations in high-risk adults.

The FDA approved asundexian (Sunharbo) with antiplatelet therapy to reduce recurrent stroke risk after noncardioembolic stroke or high-risk TIA.

The FDA granted accelerated approval to amivantamab and hyaluronidase for previously treated recurrent or metastatic head and neck cancer.

Real-world study tracks JAK inhibitors in alopecia areata and atopic dermatitis, flagging menstrual alterations and weight gain as key safety signals.

Proposals to drop race questions from the 2030 census and end EEOC workforce reporting could leave gaps in national racial data.

SGLT2 inhibitors were linked to hemoglobin gains of about 1.0 to 1.6 g/dL in small MDS and MPN studies, but a review found no randomized trials to confirm.
Advertisement
Advertisement


